# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
hours per response	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Goodwin Bradford S				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/20/2011					>	Director Officer (giv	e title below)		o Owner er (specify below	)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person  Form filed by More than One Reporting Person				
		NCISCO, CA 9								1 om med by	Wore than one	reporting reison		
(Cit	ty)	(State)	(Zip)			Table	I - Non-Deri	vative Securition	es Acquirec	l, Disposed	of, or Bene	eficially Own	ed	
(Instr. 3) Da			2. Transaction Date (Month/Day/Year		Execution Date, if		(	A) or Disposed (Instr. 3, 4 and 5)	of (D) Ow Tra				Ownership of Form:	. Nature f Indirect Beneficial Ownership
			(Working)	de V			(A) or (D)		moa. 5 and 4)		0		Instr. 4)	
							in this	s who respor form are not r s a currently	equired to	respond	unless the		ed SEC 14	474 (9-02)
			Table II -					osed of, or Beno	eficially Ov					
1. Title of Derivative Security (Instr. 3)			3A. Deemed Execution Date, if	4. Transac Code	5. Nu of De Securior Di of (D	arrants amber erivative rities ired (A) sposed ) . 3, 4,	6. Date Exe Expiration (Month/Da	nvertible secur ercisable and Date	eficially Ov	vned d Amount ying	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	Ownershi Form of Derivative Security: Direct (D) or Indirect	Beneficia Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	ts, calls, w 5. Nu of De Secur Acqu or Di of (D (Instr	arrants amber crivative cities ired (A sposed ) . 3, 4, )	6. Date Exc Expiration (Month/Da	ercisable and Date y/Year)  Expiration	7. Title an of Underly Securities	vned d Amount ying	8. Price of Derivative Security	Derivative Securities Beneficially Owned Following Reported	Ownershi Form of Derivative Security: Direct (D) or Indirect	of Indire Beneficie Ownersh (Instr. 4)

### **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Goodwin Bradford S C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X				

## **Signatures**

/s/Dolly Vance (Attorney-in-Fact)	05/20/2011
Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.